Literature DB >> 31695160

Faricimab: expanding horizon beyond VEGF.

Ashish Sharma1, Nilesh Kumar2, Baruch D Kuppermann3, Francesco Bandello4, Anat Loewenstein5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31695160      PMCID： PMC7182558          DOI： 10.1038/s41433-019-0670-1

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  10 in total

1.  Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials.

Authors:  Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Dhatri Karanam; Baruch D Kuppermann; Francesco Bandello; Carl D Regillo
Journal:  Eye (Lond)       Date:  2021-10-30       Impact factor: 3.775

2.  A systems biology model of junctional localization and downstream signaling of the Ang-Tie signaling pathway.

Authors:  Yu Zhang; Christopher D Kontos; Brian H Annex; Aleksander S Popel
Journal:  NPJ Syst Biol Appl       Date:  2021-08-20

Review 3.  Biomarkers as Predictive Factors of Anti-VEGF Response.

Authors:  Miriam Bobadilla; Ana Pariente; Ana I Oca; Rafael Peláez; Álvaro Pérez-Sala; Ignacio M Larráyoz
Journal:  Biomedicines       Date:  2022-04-26

4.  Proliferative diabetic retinopathy transcriptomes reveal angiogenesis, anti-angiogenic therapy escape mechanisms, fibrosis and lymphatic involvement.

Authors:  Ani Korhonen; Erika Gucciardo; Kaisa Lehti; Sirpa Loukovaara
Journal:  Sci Rep       Date:  2021-09-22       Impact factor: 4.379

Review 5.  Lutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration-Neurodegenerative Disease.

Authors:  Małgorzata Mrowicka; Jerzy Mrowicki; Ewa Kucharska; Ireneusz Majsterek
Journal:  Nutrients       Date:  2022-02-16       Impact factor: 5.717

6.  ANGPTL4 influences the therapeutic response of patients with neovascular age-related macular degeneration by promoting choroidal neovascularization.

Authors:  Yu Qin; Aumreetam Dinabandhu; Xuan Cao; Jaron Castillo Sanchez; Kathleen Jee; Murilo Rodrigues; Chuanyu Guo; Jing Zhang; Jordan Vancel; Deepak Menon; Noore-Sabah Khan; Tao Ma; Stephany Y Tzeng; Yassine Daoud; Jordan J Green; Gregg L Semenza; Silvia Montaner; Akrit Sodhi
Journal:  JCI Insight       Date:  2022-07-08

Review 7.  Alternative Routes of Administration for Therapeutic Antibodies-State of the Art.

Authors:  Aubin Pitiot; Nathalie Heuzé-Vourc'h; Thomas Sécher
Journal:  Antibodies (Basel)       Date:  2022-08-26

Review 8.  Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.

Authors:  Sławomir Liberski; Małgorzata Wichrowska; Jarosław Kocięcki
Journal:  Int J Mol Sci       Date:  2022-08-20       Impact factor: 6.208

Review 9.  Pharmacological agents in development for diabetic macular edema.

Authors:  Mohammad Ali Sadiq; Muhammad Sohail Halim; Muhammad Hassan; Neil Onghanseng; Irmak Karaca; Aniruddha Agarwal; Rubbia Afridi; Yasir J Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Int J Retina Vitreous       Date:  2020-07-08

Review 10.  Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders.

Authors:  Racheal Grace Akwii; Constantinos M Mikelis
Journal:  Drugs       Date:  2021-09-29       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.